Back to mobile site
Get it on Google Play

FDA approves Biofrontera's Ameluz for superficial basal cell carcinoma

September 14, 2026 9:26 AM EDT Send to a Friend
Biofrontera Inc. (NASDAQ: BFRI) announced that the U.S. Food and Drug Administration has approved a supplemental New Drug Application for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login